COPD急性加重易感人群免疫功能及高危因素研究

Study on Immune Function and Risk Factors in Acute Exacerbation of COPD in Susleptible

目的:探讨COPD急性加重易感患者与COPD急性加重非易感患者免疫功能差异,及胸腺肽肠溶片对COPD急性加重易感患者免疫功能的影响。方法:COPD急性加重易感患者与COPD急性加重非易感患者随机分成两组,分别进行免疫功能检查与比较,并给予胸腺肽肠溶片治疗COPD急性加重易感患者,治疗后检测其免疫功能,随访9个月,统计其急性加重间隔时间。结果:胸腺肽肠溶片治疗后发病间隔时间延长。治疗前、后T淋巴细胞亚群CD+4、CD+8水平及CD+4/CD+8比值间差别均有显著性意义(P<0.05)。结论:胸腺肽肠溶片是一种良好的免疫调节剂。

Objective： To explore the immune function differences between acute exacerbations of COPD in susceptible populations and in unsusceptible populations,and the effect of thymopeptides enteric-coated tablets on immune function for susceptible patients with COPD acute exacerbation. Method： Patients were randomly divided into two groups： COPD exacerbations susceptible patients and COPD exacerbations unsusceptible patients. The immune function were compared and checked respectively. The COPD exacerbations susceptible patients were given the thymopeptides enteric-coated tablets and their immune function were checked after treatment. The intervals of acute aggravating time were counted after 9 months of follow-up.Results： The interval of acute aggravating time was extended after the use of thymopeptides enteric-coated tablets. T CD ＋ 4,CD ＋ 8 level and CD ＋ 4 / CD ＋ 8 ratio of lymphocyte subgroup both had significant difference before and after treatment（ P〈0. 05）. Conclusion： The thymopeptides enteric-coated tablet is a good immune regulator.